NCT00595231View on ClinicalTrials.gov

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

PHASE2CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

SYN111

500 mg for 1 week followed by 1000 mg for 7 weeks

DRUG

Placebo

0 mg tablets

Trial Locations (2)

30080

Carmen Research, Atlanta

45408

Midwest Clinical Research Center, Dayton

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Biotie Therapies Inc.

INDUSTRY